IGM Biosciences Announces Second Quarter 2021 Financial Results and Provides Corporate Update
August 09, 2021 16:06 ET
|
IGM Biosciences, Inc.
– Recommended Phase 2 Dose of IGM-2323 Expected in 2021 – – Initial Data from Phase 1 Trial of IGM-8444 in Solid Cancers Expected in 2021 – – Expansion of IgM Platform into Infectious Diseases – ...
IGM Biosciences Announces the Appointment of Chris H. Takimoto, M.D., Ph.D., F.A.C.P., as Chief Medical Officer
July 29, 2021 17:31 ET
|
IGM Biosciences, Inc.
MOUNTAIN VIEW, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
IGM Biosciences Announces Expansion of IgM Platform into Infectious Diseases, Publication of Preclinical Data in Nature Demonstrating Engineered IgM Antibody Antiviral Activity for the Treatment and Prevention of COVID-19
June 03, 2021 07:01 ET
|
IGM Biosciences
MOUNTAIN VIEW, Calif., June 03, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS) a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
IGM Biosciences to Present at the Jefferies Virtual Healthcare Conference
May 26, 2021 07:00 ET
|
IGM Biosciences
MOUNTAIN VIEW, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
IGM Biosciences to Present at the 2021 RBC Capital Markets Global Healthcare Conference
May 12, 2021 07:00 ET
|
IGM Biosciences
MOUNTAIN VIEW, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
IGM Biosciences Announces First Quarter 2021 Financial Results and Provides Corporate Update
May 06, 2021 16:07 ET
|
IGM Biosciences
– Recommended Phase 2 Dose of IGM-2323 Expected in 2021 – – Initial Data from Phase 1 Trial of IGM-8444 in Solid Cancers Expected in 2021 – – IND Filing for IGM-7354 Planned in 2021 – MOUNTAIN...
IGM Biosciences to Present at the Truist Securities Life Sciences Summit
April 27, 2021 07:00 ET
|
IGM Biosciences
MOUNTAIN VIEW, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
IGM Biosciences Appoints George Gauthier as Chief Commercial Officer
April 12, 2021 07:00 ET
|
IGM Biosciences
MOUNTAIN VIEW, Calif., April 12, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...
IGM Biosciences Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
March 30, 2021 16:17 ET
|
IGM Biosciences
– Recommended Phase 2 Dose for IGM-2323 Expected in 2021 – – Initial Data from Phase 1 Trial of IGM-8444 in Solid Cancers Expected in 2021 – – IND Filing for IGM-7354 Planned in 2021 – – Company to...
IGM Biosciences to Announce Fourth Quarter and Year-end 2020 Financial Results and Host Conference Call and Webcast on March 30, 2021
March 24, 2021 07:00 ET
|
IGM Biosciences
MOUNTAIN VIEW, Calif., March 24, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies,...